| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Levin Ilan | Director, 10%+ Owner | C/O SILEXION THERAPEUTICS CORP, 12 ABBA HILLEL ROAD, RAMAT GAN, ISRAEL | /s/ Ilan Levin | 27 Jan 2026 | 0001849189 |
| Moringa Sponsor, LP | 10%+ Owner | C/O MORINGA ACQUISITION CORP, 250 PARK AVENUE, 7TH FLOOR, NEW YORK | Moringa Sponsor, LP, by Moringa Partners Ltd., its sole general partner, by: /s/ Ilan Levin, director | 27 Jan 2026 | 0001849192 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLXN | Ordinary Shares | Other | $0 | -5,550 | -44% | $0.000000 | 6,970 | 07 Aug 2025 | By Moringa Sponsor, LP. | F1, F2, F3 |
| transaction | SLXN | Ordinary Shares | Award | $1,800,000 | +450,000 | +6456% | $4.00 | 456,970 | 15 Sep 2025 | By Moringa Sponsor, LP. | F2, F3, F4 |
| holding | SLXN | Ordinary Shares | 1,482 | 07 Aug 2025 | By Greenstar, L.P. | F2, F5, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLXN | Warrant (right to buy) | Other | $0 | -935 | -72% | $0.000000 | 372 | 07 Aug 2025 | Ordinary Shares | 935 | $1552.50 | By Moringa Sponsor, LP. | F1, F3, F7 |
| Id | Content |
|---|---|
| F1 | The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP. |
| F2 | The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. |
| F3 | Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein. |
| F4 | The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares. |
| F5 | There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| F6 | Moringa Partners Ltd. serves as the sole general partner of Greenstar, L.P. As a result of Ilan Levin being the sole equity owner and serving as the sole director of Moringa Partners Ltd. (as described in footnote (3) above), Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares. The limited partnership interests of Greenstar, L.P. may be held from time to time by various individuals and entities. Mr. Levin disclaims beneficial ownership of the subject ordinary shares except to the extent of his indirect pecuniary interest therein. |
| F7 | The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. |